If the desired results are not seen after 3-6 months, or if the patient cannot tolerate the medication, discontinuation or alternative treatments may be considered
Weight loss typically begins in earnest at the 0.5 mg or 1.0 mg dose level
Total semaglutide used during this phase: 2.0 mg (4 injections of 0.50 mg) Cumulative total through week 8: 3.0 mg Weeks 9 to 12: the therapeutic threshold (1.0 mg per week) This is where the protocol gets serious
No overall differences in safety or efficacy were detected between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out
However, treatment options remain limited, therefore the discovery and development of new treatments for ASUDs is of critical importance Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and GLP-1/GIP (glucose-dependent insulinotropic peptide) agonist currently approved for the treatment of type 2 diabetes mellitus, obesity, and obstructive sleep apnea, have recently emerged as potential new pharmacotherapies for ASUDs
